Home Featured Page 141

Featured

Latest

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke...

Israel-Based Clearmind Announces Additional Positive Results from the Third Part of...

PT382 – The Body & Catharsis: Do We Need Psychedelics or...

First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular...

Revive Therapeutics legt aktualisiertes Informationspaket zur Unterstützung der bevorstehenden Sitzung des...

Psychedelic Bulletin #129: New Year, New Psychedelic Bills; WHO Dubs 5-MeO-DMT...

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

Psychedelics Weekly – Prince Harry and Psychedelics, Proposed Legalization, and The...

Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from...

EDITOR PICKS

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke...

Israel-Based Clearmind Announces Additional Positive Results from the Third Part of...

PT382 – The Body & Catharsis: Do We Need Psychedelics or...

First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular...

Revive Therapeutics legt aktualisiertes Informationspaket zur Unterstützung der bevorstehenden Sitzung des...

Psychedelic Bulletin #129: New Year, New Psychedelic Bills; WHO Dubs 5-MeO-DMT...

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

Psychedelics Weekly – Prince Harry and Psychedelics, Proposed Legalization, and The...

Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from...

EDITOR PICKS

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY